RE:RE:RE:RE:RE:what we know as factsNone taken. The 52 week high of $32.50 @ 55M Market Cap. What was on the plate then pales in comparison to what's on the plate now. Too much backwards thinking going on here. It's not that complicated to realize the situation has changed for the better. Nobody is saying the CEO needs to walk on water. He simply needs to execute what';s written in a timely manner. The Phase 1 clinical trials should not be a bogged down situation because only a handful of participants are needed to execute the plan. Also, none of the clinical trials are being run in AU/NZ and Algernon has hired it's own experts to guide the Phase 2 DMT/Stroke clinical trial. There was no one overseeing the COVID study or IPF/CC. Which means they are not taking any chances of a screw up with the DMT program. Once uplisted to Nasdaq, I'm done posting here. The narrative will have shifted to the point of not needing to hold others hand moving forward >>>
The Company also announces it has appointed Dr. Anthony Rudd and Dr. Robert Simister, both from the U.K., as medical consultants to the Company’s DMT stroke clinical research program. Both Dr. Rudd and Dr. Simister have extensive backgrounds in stroke management as well as clinical care and stroke research. Their primary responsibility will be to help guide the Company’s Phase 2 acute stroke and post stroke therapy clinical trials planned to begin in the U.K. in the latter part of 2022, after the Phase 1 trial has been completed.